Munich

MorphoSys to buy Constellation Pharma in a $1.7B bet on epigenetic cancer drugs

MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the acquisition with cash from a separate $2 billion deal with drug royalty acquirer Royalty Pharma.

With new funding, digital physical therapy startup Kaia strikes partnerships with clinicians  

Kaia Health, a startup providing app-based programs for musculoskeletal conditions and COPD, recently raised $75 million in funding. As competitors look to round out their platforms with other services, Kaia is looking to strike partnerships with clinicians. 

FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population

The FDA approved Monjuvi for second-line diffuse large B-cell lymphoma. Though the drug has the same antigen target as approved CAR-T cell therapies, it is designed for patients unable to tolerate such intensive treatments.

Digital health startup Kaia hopes to win over insurers with results of back pain study

Kaia Health, a startup making an app to help users manage back pain, touted the results of a large, randomized controlled trial using its app. The company currently markets its system to employers, but hopes to make it available as a covered benefit in the future.